Calidi Biotherapeutics, Inc. (CLDI) Stock Price & How to Invest

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company based in San Diego, California, developing therapies that combine oncolytic viruses with cell-based delivery to target hard-to-treat cancers. Its approach is built on the idea of shielding therapeutic viruses inside stem cells so they can survive the immune system long enough to reach and destroy tumors. The pipeline includes CLD-101 (NeuroNova), studied in Phase 1 for high-grade glioma, an aggressive brain cancer; CLD-201 (SuperNova), an allogeneic stem-cell-loaded viral therapy for solid tumors such as soft tissue sarcoma, triple-negative breast cancer, and head and neck cancer; and RTNova (CLD-400), an earlier-stage systemic platform using an enveloped virotherapy designed for intravenous, potentially redosable delivery to metastatic and lung cancers. The company generates no product revenue and is years away from any potential approval.

Calidi became publicly traded in 2023 through a merger with a special purpose acquisition company (SPAC) and trades on NYSE American. Recent developments include FDA clearance of an investigational new drug application for CLD-201 in April 2025 and FDA Fast Track designation for CLD-201 in soft tissue sarcoma in July 2025, plus ongoing preclinical work on RTNova and a related lead candidate engineered to deliver an IL-15 immune-stimulating payload. The financial reality is stark: the company reported a net loss of about $25.6 million for 2025 and ended the year with roughly $5.6 million in cash, with about $6.9 million in cash and restricted cash reported as of March 31, 2026. It has flagged substantial doubt about its ability to continue as a going concern, carries a large overhang of warrants, and completed a 1-for-12 reverse stock split in August 2025 to maintain its share-price listing standard. Operations are funded through repeated, dilutive equity raises.

Calidi is a pre-revenue, clinical-stage micro-cap whose value depends almost entirely on early-stage trial outcomes, so a single clinical failure, safety signal, or program delay could sharply reduce the stock. The company has reported substantial doubt about its ability to continue as a going concern, ended 2025 with only about $5.6 million in cash against ongoing losses, and funds itself through repeated dilutive equity raises that erode existing shareholders; it also carries a large warrant overhang and completed a 1-for-12 reverse stock split in August 2025 to maintain its listing standard, with continued delisting risk if the share price falls again. There is no product revenue, no profit, and no certainty that any program will ever be approved or commercialized. This is among the most speculative categories of stock, and a total or near-total loss is a realistic outcome.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Calidi Biotherapeutics, Inc.'s investor relations page or your broker.

• Revenue: None (no approved products; pre-revenue clinical-stage)
• Net loss (FY 2025): ~$25.6 million (vs. ~$23.8 million in 2024)
• Cash & equivalents: ~$5.6 million at year-end 2025; ~$6.9 million cash and restricted cash at March 31, 2026
• Cash runway: Very limited; company has flagged substantial doubt about going concern and relies on ongoing financings
• Market cap: Micro-cap, roughly a few million dollars in early 2026; moves sharply on news and financings
• Share structure: 1-for-12 reverse split effective August 2025; large warrant overhang (tens of millions of warrants outstanding)

A pre-revenue clinical biotech like Calidi cannot be valued on earnings, because there are none; metrics like P/E are not meaningful. Investors who study these companies typically weigh the cash runway against the quarterly burn rate, the timing and probability of upcoming clinical catalysts (such as trial starts, data readouts, and FDA designations), and the dilution required to fund the next stage of development. For Calidi specifically, the very low cash balance, going-concern doubt, reverse split, and heavy warrant overhang mean financing risk and dilution are central to any assessment, and the stock can swing dramatically on capital raises as much as on science.

There are three common ways to get CLDI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CLDI sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where CLDI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Calidi Biotherapeutics is a pre-revenue, clinical-stage cancer-virotherapy company whose value depends on early trial data and its ability to keep funding operations. It behaves as a binary, highly speculative micro-cap: shares can move sharply on pipeline news or financing events, and the company has limited cash, ongoing dilution, and going-concern doubt that make outcomes extremely uncertain.

Whether CLDI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CLDI a buy?, and where the stock could go from here in the CLDI stock forecast.

For income investors, whether CLDI pays a dividend and how the payout looks is covered in does CLDI pay a dividend?